المؤلفون: Nomathemba Chandiwana, Natasha Arulappan, Matthew Chersich, Bryony Simmons, Masebole Masenya, Michelle Moorhouse, Shane A. Norris, Polly Clayden, Ambar Qavi, Simiso Sokhela, Willem D F Venter, Celicia Serenata, Elaine J. Abrams, Godspower Akpomiemie, Kaitlyn McCann, Nkuli Mashabane, Samanta T. Lalla-Edward, Lee Fairlie, Andrew Hill, Gary Maartens, Alinda G. Vos

المصدر: The Lancet HIV. 7:e666-e676

مصطلحات موضوعية: Cyclopropanes, Male, 0301 basic medicine, Epidemiology, HIV Infections, Piperazines, law.invention, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, immune system diseases, law, Antiretroviral Therapy, Highly Active, Emtricitabine, 030212 general & internal medicine, Alanine, virus diseases, Middle Aged, Viral Load, Treatment Outcome, Infectious Diseases, Alkynes, Dolutegravir, Body Composition, Female, Heterocyclic Compounds, 3-Ring, Viral load, medicine.drug, Adult, medicine.medical_specialty, Efavirenz, Adolescent, Anti-HIV Agents, Pyridones, Immunology, Tenofovir alafenamide, Young Adult, 03 medical and health sciences, Virology, Internal medicine, Oxazines, medicine, Humans, Tenofovir, Adverse effect, Duration of Therapy, business.industry, Adenine, Body Weight, 030112 virology, Benzoxazines, Regimen, chemistry, HIV-1, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d05d0fad98edf7ad40a319200d5374a
https://doi.org/10.1016/s2352-3018(20)30241-1